Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Anel Muterspaugh"'
Autor:
Rafael Paez, Chirayu Shah, Angelina J. Cords, Anel Muterspaugh, John E. Helton, Sanja Antic, Rosana Eisenberg, Heidi Chen, Eric L. Grogan, Henry C. Manning, Ronald C. Walker, Pierre P. Massion
Publikováno v:
PLoS ONE, Vol 17, Iss 3 (2022)
Background 18F-fluorodeoxyglucose (FDG) PET/CT is recommended for evaluation of intermediate-risk indeterminate pulmonary nodules (IPNs). While highly sensitive, the specificity of FDG remains suboptimal for differentiating malignant from benign nodu
Externí odkaz:
https://doaj.org/article/4a8fe88963fd4a9da8bcb3f6593e791a
Autor:
Jarrod T. Smith, BA, Aneri Balar, MD, Dhairya A. Lakhani, MD, Christien Kluwe, MD, PhD, Zhiguo Zhao, MS, Prasad Kopparapu, PhD, Karinna Almodovar, PhD, Anel Muterspaugh, MPH, CPH, Yingjun Yan, MS, Sally York, MD, PhD, Leora Horn, MD, MSc, Sanja Antic, MS, Caterina Bertucci, MPA, Tristan Shaffer, MS, Lauren Hodsdon, MPH, Kavita Garg, PhD, Seyed Ali Hosseini, MD, PhD, Lee Lim, PhD, Evan Osmundson, MD, PhD, Pierre P. Massion, MD, Christine M. Lovly, MD, PhD, Wade Iams, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100110- (2021)
Introduction: Blood-based next-generation sequencing assays of circulating tumor DNA (ctDNA) have the ability to detect tumor-associated mutations in patients with SCLC. We sought to characterize the relationship between ctDNA mean variant allele fre
Externí odkaz:
https://doaj.org/article/30a2425056284f07b711aa00850a555d
Autor:
Wade T. Iams, MD, Prasad R. Kopparapu, PhD, Yingjun Yan, MS, Anel Muterspaugh, MPH, Zhiguo Zhao, MS, Heidi Chen, PhD, Christopher Cann, MD, Sally York, MD, PhD, Leora Horn, MD, MS, Kristin Ancell, MD, Kenneth Wyman, MD, Caterina Bertucci, MPA, Tristan Shaffer, MS, Lauren A. Hodsdon, MPH, Kavita Garg, PhD, Seyed Ali Hosseini, MD, PhD, Lee P. Lim, PhD, Christine M. Lovly, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100024- (2020)
Introduction: Most patients (70%) with limited-stage SCLC (LS-SCLC) who are treated with curative-intent therapy suffer disease relapse and cancer-related death. We evaluated circulating tumor DNA (ctDNA) as a predictor of disease relapse and death a
Externí odkaz:
https://doaj.org/article/4458f029679347a28119d2847325d282
Autor:
Dhairya A. Lakhani, Chirayu Shah, Sheau-Chiann Chen, Eric L. Grogan, Sophie Jouan, Stephen A. Deppen, Anthony Disher, Luis E. Huerta, Sarah Atmajoana, Khushbu Patel, Alexandra Miller, Hina Shujat, Katrina Brewer, Janelle Wenstrup, Nancy Liu, Rajbir Singh, Heidi Chen, Subodh Nag, Alexis B. Paulson, John T Helton, Kim L. Sandler, Richard D. Fremont, Anel Muterspaugh, Sara L Block, Otis B. Rickman, Melinda C. Aldrich, Rosana Eisenberg, Pierre P. Massion, Sanja L. Antic, Aneri B. Balar, Christine M. Cook, Ronald C. Walker, Gary T. Smith, Bennett A. Landman, Kim Fields, Amy Hinton, Brandon Winston
Publikováno v:
Ann Am Thorac Soc
Rationale: A prospective longitudinal cohort of individuals at high risk of developing lung cancer was established to build a biorepository of carefully annotated biological specimens and low-dose computed tomography (LDCT) chest images for derivatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::718a007a590572294c64a9ed3f472777
https://pubmed.ncbi.nlm.nih.gov/33400907
https://pubmed.ncbi.nlm.nih.gov/33400907
Autor:
Prasad R. Kopparapu, Tristan Shaffer, Anel Muterspaugh, Christopher G. Cann, Kenneth Wyman, Lauren Hodsdon, Heidi Chen, Wade T. Iams, Zhiguo Zhao, Yingjun Yan, Sally York, Leora Horn, Lee P. Lim, Kavita Garg, Christine M. Lovly, Kristin K. Ancell, Seyed Ali Hosseini, Caterina Bertucci
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100024-(2020)
JTO Clinical and Research Reports
JTO Clinical and Research Reports
Introduction Most patients (70%) with limited-stage SCLC (LS-SCLC) who are treated with curative-intent therapy suffer disease relapse and cancer-related death. We evaluated circulating tumor DNA (ctDNA) as a predictor of disease relapse and death af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e19cbe9ad4d13d8542e46b7acf0c68cd
http://www.sciencedirect.com/science/article/pii/S2666364320300242
http://www.sciencedirect.com/science/article/pii/S2666364320300242
Autor:
Dhairya A. Lakhani, Wade T. Iams, Karinna Almodovar, Christien Kluwe, Aneri B. Balar, Evan C. Osmundson, Leora Horn, S. Antic, Prasad R. Kopparapu, Anel Muterspaugh, Jarrod T. Smith, Zhiguo Zhao, Seyed Ali Hosseini, Lauren Hodsdon, Lee Lim, Christine M. Lovly, Caterina Bertucci, Pierre P. Massion, Kavita Garg, Yingjun Yan, Sally York, Tristan Shaffer
Publikováno v:
JTO Clinical and Research Reports
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100110-(2021)
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100110-(2021)
Introduction: Blood-based next-generation sequencing assays of circulating tumor DNA (ctDNA) have the ability to detect tumor-associated mutations in patients with SCLC. We sought to characterize the relationship between ctDNA mean variant allele fre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f959ac8ac1eedf959c4b9ef743d398a
https://pubmed.ncbi.nlm.nih.gov/34589992
https://pubmed.ncbi.nlm.nih.gov/34589992
Autor:
Pierre P. Massion, Tristan Shaffer, Prasad R. Kopparapu, Jarrod T. Smith, Evan C. Osmundson, Yingjun Yan, Sally York, Dhairya A. Lakhani, Kavita Garg, Christine M. Lovly, Zhiguo Zhao, Christien Kluwe, Sanja L. Antic, Lee Lim, Caterina Bertucci, Aneri B. Balar, Leora Horn, Wade T. Iams, Seyed Ali Hosseini, Anel Muterspaugh, Lauren Hodsdon, Karinna Almodovar
Publikováno v:
Cancer Research. 80:715-715
Introduction Blood-based next generation sequencing assays of circulating tumor DNA (ctDNA) have the ability to detect canonical SCLC tumor-associated mutations1,2. In non-small cell lung cancer, mean variant allele frequency (VAF) of clonal mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fabe505148ccd565004c930b2da9120
https://doi.org/10.1158/1538-7445.am2020-715
https://doi.org/10.1158/1538-7445.am2020-715
Autor:
Caterina Bertucci, Anel Muterspaugh, Kenneth Wyman, Prasad R. Kopparapu, Kavita Garg, Wade T. Iams, Kristen Ancell, Christine M. Lovly, Christopher G. Cann, Lee Lim, Yingjun Yan, Sally York, Leora Horn, Heidi Chen, Zhiguo Zhao, Tristan Shaffer, Seyed Ali Hosseini, Lauren Hodson
Publikováno v:
Clinical Cancer Research. 26:B20-B20
Introduction: Despite recent incremental advances, patients with small-cell lung cancer (SCLC) continue to have a poor prognosis, with a median overall survival (OS) of 12-20 months in limited-stage disease (LS-SCLC) and approximately 12 months in ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc228a266728a039850d7bdfadb5b492
https://doi.org/10.1158/1557-3265.liqbiop20-b20
https://doi.org/10.1158/1557-3265.liqbiop20-b20
Publikováno v:
Chest. 142:639A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18a82c1c65bb7b4e330e3be36633eed2
https://doi.org/10.1378/chest.1390675
https://doi.org/10.1378/chest.1390675